SN

Shri Niwas

Director Director DIN 01153422
DIN 01153422 First appointment Aug 2004 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Aug 2004
Shareholding value •••• Premium profile

About Shri Niwas

Data last updated:

Shri Niwas was a Director at Attollent Pharmaceuticals Private Limited (2022–2025) and Director at Gene Laboraties Limited (2004–2008). The companies operate in Trading and Healthcare.

DIN 01153422
Primary Designation Director
Industry Trading
First Appointment 20 Aug 2004

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Apr 20222011₹3.18 Cr (FY 2025)Active
Gene Laboraties Limited U85195RJ2000PLC016401
Director20 Aug 20042000Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Attollent Pharmaceuticals Private Limited
Gene Laboraties Limited
Premium access

Shareholding and investment profile for Shri Niwas

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shri Niwas

Shri Niwas was first appointed on 20 Aug 2004 as Director at Gene Laboraties Limited. The most recent appointment on record is 30 Apr 2022 at Attollent Pharmaceuticals Private Limited.

Shri Niwas held 2 earlier board appointments: Attollent Pharmaceuticals Private Limited (Director, 30 Apr 2022 to 06 Feb 2025); Gene Laboraties Limited (Director, 20 Aug 2004 to 30 Jun 2008).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available